Halozyme Scores Legal Win Against Merck’s Keytruda SC in Germany

Halozyme Therapeutics, Inc., a biotechnology company, has achieved a crucial legal victory in Germany by obtaining a preliminary injunction against Merck’s Keytruda SC, a subcutaneous form of the popular cancer immunotherapy drug Keytruda. This court decision temporarily prevents Merck from selling Keytruda SC in the German market.

The injunction is grounded in patent infringement claims, with Halozyme asserting that Merck’s product violates its proprietary Enhanze enzyme technology. This patented technology enables subcutaneous drug administration and has played a vital role in the success of various biopharmaceutical products.

Significance of the Ruling

The German court’s preliminary injunction suggests the following:

• The court found Halozyme’s patent claims credible enough to issue an early intervention.
• Merck is barred from using delivery methods involving Enhanze technology under Halozyme’s patents.
• The ruling has immediate commercial implications by restricting sales of Keytruda SC in Germany.

Keytruda is widely used for treating cancers such as melanoma and lung cancer. Merck’s SC formulation aimed at enhancing patient convenience by shortening administration time compared to intravenous infusion. However, the injunction will maintain reliance on existing intravenous formulations in Germany until the dispute concludes.

Industry Impact and Next Steps

This case highlights several important aspects:

1. The strategic importance of patent portfolios in pharmaceutical drug delivery technologies.
2. The potential for this ruling to set a precedent in intellectual property disputes within Europe.
3. Ongoing legal proceedings are expected between Halozyme and Merck to resolve the patent conflict fully.

Healthcare providers and patients in Germany currently must continue using traditional Keytruda formulations while monitoring the situation. This ruling underscores the critical role of intellectual property protection in fostering innovation within the biotech and pharmaceutical industries.

About The Author